The Erlanger Health System (often referred to as Erlanger Hospital or simply Erlanger), incorporated as the Chattanooga-Hamilton County Hospital Authority, a non-profit, public benefit corporation registered in the State of Tennessee, is an academic system of hospitals, physicians, and medical services based in Chattanooga, Tennessee. Erlanger is a tertiary referral hospital and Level I Trauma Center serving a 50,000 sq mi (130,000 km2) (125 mi (201 km) radius) region of East Tennessee, North Georgia, North Alabama, and western North Carolina. The system's critical care services are accessible to patients within a 150 mi (240 km) radius through six Life Force air ambulance helicopters, each equipped to perform in-flight surgical procedures and transfusions.Founded in 1889, Erlanger is a large public healthcare system with more than half a million patient visits a year.
Diuretics are integral in fluid de-resuscitation of ICU patients following initial stabilization. While loop diuretics are commonly used, sequential nephron blockade (SNB) is an alternative diuretic strategy that combines a loop diuretic with at least one diuretic from another pharmacologic class to increase efficacy and limit adverse effects. The objective of this study was to compare the safety and efficacy of SNB to loop diuretics alone for de-resuscitation of critically ill patients. This retrospective study included adult ICU patients who received either a loop diuretic alone or combined with an aldosterone antagonist, carbonic anhydrase inhibitor, and/or thiazide diuretic on two consecutive days. The primary outcome was comparison of diuretic efficacy, assessed by urine output, on diuresis day 1. Secondary outcomes included comparison of diuretic efficacy on diuresis days 2-5 and incidence of acute kidney injury and electrolyte abnormalities on diuresis day 1. A total of 100 patients were included (SNB = 15, Loop = 85). At baseline, SNB patients had more hypernatremia (20% vs 2.4%, P = 0.023) and hyperchloremia (20% vs 2.4%, P = 0.023). Patients in the SNB group had increased urine output on diuresis day 1 (4725 vs 2215 mL, P = 0.0004). AKI did not occur in SNB patients on diuresis day 1 vs 15.5% of loop patients (P = 0.208). Hypernatremia (26.7% vs 2.4%, P = 0.004) and hyperchloremia (13.3% vs 3.5%, P = 0.161), persisted in the SNB group on diuretic day 2. In conclusion, among ICU patients requiring de-resuscitation, SNB may be associated with improved diuresis and similar safety concerns compared to loop diuretics alone.
Abstract Introduction 0.05% Chlorhexidine Gluconate (CHG) has gained popularity as an irrigant and dip for inflatable penile prosthesis (IPP) surgery. Prior in vitro data is conflicting on the impact of CHG use with hydrophilic coated devices. Objective We sought to identify possible associations between CHG use and hydrophilic IPP infection rate. Methods We conducted a retrospective cohort study of 2,933 patients undergoing IPP implantation across 14 referral centers. Data collection spanned from January 1, 2017 to March 1, 2024. Each surgeon contributed patients who underwent IPP implantation with CHG used as an irrigant and/or dip as well as an equal number of consecutive control patients without CHG use. The primary outcome was IPP explant for postoperative infection. Univariable analysis was used to compare patient demographics, and logistic regression analysis was performed to assess factors associated with infection. Results Hydrophilic devices were implanted in 2,150 patients. Median follow-up for non-CHG patients was 13 months (IQR 18) and four months (IQR 9) for CHG patients. The incidence of infection with intraoperative CHG use was significantly higher compared to those without CHG use (4.6%, 46/1,001 vs. 2.1%, 24/1,148, p<0.001). On multivariable logistic regression analysis, intraoperative CHG use was associated with infection (OR 2.07, 95% CI 1.24-3.47, p=0.01). Additional variables associated with infection included immunosuppression, prior IPP infection, prior priapism, and revision surgery (p<0.01, Table). On subgroup analyses, the increased infection risk of CHG was most clear when CHG was used as both irrigation and dip (OR 2.03, 95% CI 1.19-3.46, p=0.01) and when CHG was used during revision surgery (OR 3.36, 95% CI 1.15-9.82, p=0.03). Conclusions In a large multi-institutional cohort, intraoperative CHG use was associated with an elevated incidence of hydrophilic IPP infection. Providers may take these findings into consideration when performing IPP surgery with hydrophilic devices, especially during revision surgery. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Intuitive Surgical, Fidelis, Urofill, Boston Scientific, Coloplast, Cynosure, Antares Pharma, Clarus Pharmaceuticals, Acerus Pharma; Endo Pharma
Abstract Background and aims Although intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT) improve outcomes, many patients with ischemic stroke remain ineligible, lack access, or have persistent disability. Rinvecalinase alfa (DM199), recombinant human tissue kallikrein-1, may augment cerebral perfusion via bradykinin-mediated signaling and promote vascular repair, potentially improving outcomes and reducing stroke recurrence. Methods ReMEDy2 evaluates safety and efficacy of DM199 versus placebo in acute ischemic stroke. Results ReMEDy2 is a global, Phase 2/3 adaptive, randomized, double-blind, placebo-controlled trial. Adults presenting within 24 hours of stroke onset with National Institutes of Health Stroke Scale (NIHSS) scores of 5-15 are randomized 1:1 to DM199 or placebo, both receiving standard care. Patients with large vessel occlusion or early clinical improvement after IVT are excluded. Study intervention is a single intravenous dose followed by twice-weekly subcutaneous injections through Day 21. Conclusions The primary endpoint is excellent stroke recovery at 90 days (modified Rankin Scale [mRS] score of 0-1). Secondary outcomes include 90-day mRS shift, NIHSS, Barthel Index, recurrent stroke, mortality, and safety. Conflict of interest